Table 1.
Similarities between COVID-19 and pulmonary hypertension
COVID-19 | PH | |
---|---|---|
Symptom | ||
Dyspnea | +++ | +++ |
Fatigue | +++ | + |
Inflammation | ||
Endotheliitis | +++ | +* |
Vasculitis | +++ | +* |
Myocarditis | + | − |
Proinflammatory cytokines | ↑↑↑ | ↑↑† |
Thrombosis, microthrombi | ||
D-dimers | ↑↑↑ | ↑ |
Prothrombin | ↑ | ↑ |
DNA damage | ||
PARP | ↑ | ↑↑ |
RAA activation | + | +++ |
ACE 2 | ↓↓ | ↓ |
Angiotensin 2 | ↑↑↑ | ↑↑ |
Cardiac injury | ||
Ejection fraction | ↓* | ↓‡ |
Troponin | ↑↑ | ↑ |
Natriuretic peptide | ↑ | ↑↑↑ |
RV dilatation | ↑ | ↑↑↑ |
Pulmonary vascular thickness | ↑ | ↑↑↑ |
Mitochondrial dysfunction | ↑ | ↑↑ |
ROS | ↑ | ↑↑ |
Endothelial dysfunction | ↑ | ↑↑ |
HPV | ↑ | ↑↑↑§ |
HPV, hypoxic pulmonary vasoconstriction; PARP, poly-ADP ribose polymerase; PH, pulmonary hypertension; RAA, renin-angiotensin-aldosterone system; ROS, reactive oxygen species; RV, right ventricle.
Occasionally;
group 1 pulmonary hypertension;
group 2 pulmonary hypertension;
group 3 pulmonary hypertension.
↑ increased, ↑↑ generally increased, ↑↑↑ frequently increased, ↓ decreased, + observed, ++ generally observed, +++, frequently observed.